LiuJY, ParkSH, MorisseauC, et al.: Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther, 2009; 8:2193–2203.
7.
HsiehCH, LinYJ, ChenWL, et al.: HIF-1α triggers long-lasting glutamate excitotoxicity via system xc- in cerebral ischaemia-reperfusion. J Pathol, 2016 [Epub ahead of print]. DOI:10.1002/path.4838.
8.
SimsB, ClarkeM, FrancillionL, et al.: Hypoxic preconditioning involves system Xc- regulation in mouse neural stem cells. Stem Cell Res, 2012; 8:285–291.
9.
SoriaFN, Pérez-SamartínA, MartinA, et al.: Extrasynaptic glutamate release through cystine/glutamate antiporter contributes to ischemic damage. J Clin Invest, 2014; 124:3645–3655.
10.
RyuBR, LeeYA, WonSJ, et al.: The novel neuroprotective action of sulfasalazine through blockade of NMDA receptors. J Pharmacol Exp Ther, 2003; 305:48–56.
11.
DöbbelingU, Waeckerle-MenY, ZabelF, et al.: The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. Exp Dermatol, 2013; 22:119–124.
12.
EllegaardAM, DehlendorffC, VindAC, et al.: Repurposing cationic amphiphilic antihistamines for cancer treatment. EBioMedicine, 2016; 9:130–139.
13.
KongX, ChenL, JiaoL, et al.: Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2. J Med Chem, 2014; 57:9512–9521.
GroppeJC, WuJ, ShoreEM, KaplanFS: In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs, 2011; 194:291–295.
16.
SanvitaleCE, KerrG, ChaikuadA, et al.: A new class of small molecule inhibitor of BMP signaling. PLoS One, 2013; 8:e62721.
17.
BillichA: Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs, 2007; 10:53–59.
18.
CaiX, XuY, CheungAK, et al.: PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling. Chem Biol, 2013; 20:912–921.
19.
VaccariI, DinaG, TronchèreH, et al.: Genetic interaction between MTMR2 and FIG4 phospholipid phosphatases involved in Charcot-Marie-Tooth neuropathies. PLoS Genet, 2011; 7:e1002319.
20.
KrauszS, BoumansMJ, GerlagDM, et al.: Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum, 2012; 64:1750–1755.
21.
SahinH, BerresML, WasmuthHE: Therapeutic potential of chemokine receptor antagonists for liver disease. Expert Rev Clin Pharmacol, 2011; 4:503–513.
22.
ZimmermannHW, TackeF: Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets, 2011; 10:509–536.
23.
FriedmanS, SanyalA, GoodmanZ, et al.: Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials, 2016; 47:356–365.
24.
LefebvreE, MoyleG, ReshefR, et al.: Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One, 2016; 11:e0158156.
25.
RubinP, CasarettGW: Clinical radiation pathology as applied to curative radiotherapy. Cancer, 1968; 22:767–778.
26.
NagarS, CorcoranJJ, MorganWF: Evaluating the delayed effects of cellular exposure to ionizing radiation. Methods Mol Biol, 2006; 314:43–50.
27.
DelanianS, LefaixJL: Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol, 2007; 17:99–107.
28.
ChiangCL, ChenYW, WuMH, et al.: Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer. J Chin Med Assoc, 2016; 79:248–255.
29.
Strup-PerrotC, VozeninMC, MonceauV, et al.: PrP(c) deficiency and dasatinib protect mouse intestines against radiation injury by inhibiting of c-Src. Radiother Oncol, 2016; 120:175–183.
30.
LinHW, TsengCH: A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol, 2014; 2014:719578.
31.
SaltIP, JohnsonG, AshcroftSJ, HardieDG: AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J, 1998; 335:533–539.
32.
VillaniLA, SmithBK, MarcinkoK, et al.: The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab, 2016; 5:1048–1056.
33.
BensonSC, PershadsinghHA, HoCI, et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004; 43:993–1002.
34.
WeissJ, SauerA, DivacN, et al.: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos, 2010; 31:150–161.
35.
JonesMR, SchraderKA, ShenY: Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Ann Oncol, 2016; 27:801–806.
WenJ, ScolesDR, FacelliJC: Effects of the enlargement of polyglutamine segments on the structure and folding of ataxin-2 and ataxin-3 proteins. J Biomol Struct Dyn [Epub ahead of print]; DOI: 10.1080/07391102.2016.1152199.
38.
Teixeira-CastroA, AilionM, JallesA: Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet, 2011; 20:2996–3009.
39.
Silva-FernandesA, Duarte-SilvaS, Neves-CarvalhoA, et al.: Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado–Joseph disease. Neurotherapeutics, 2014; 11:433–449.
40.
HutchinsonMR, ZhangY, ShridharM, et al.: Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun, 2010; 24:83–95.
41.
SelfridgeBR, WangX, ZhangY, et al.: Structure-activity relationships of (+)-naltrexone-inspired toll-like receptor 4 (TLR4) antagonists. J Med Chem, 2015; 58:5038–5052.
42.
BeniasPC, GopalK, BodenheimerHJr, TheiseND: Hepatic expression of toll-like receptors 3, 4, and 9 in primary biliary cirrhosis and chronic hepatitis C. Clin Res Hepatol Gastroenterol, 2012; 36:448–454.
